Financials EirGenix Inc.

Equities

6589

TW0006589005

Pharmaceuticals

End-of-day quote Taipei Exchange 18:00:00 2024-05-16 EDT 5-day change 1st Jan Change
83.1 TWD +2.34% Intraday chart for EirGenix Inc. +3.88% -17.31%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 4,647 9,700 33,476 37,428 30,748 25,442 -
Enterprise Value (EV) 1 5,338 9,800 26,978 31,421 30,748 20,109 20,185
P/E ratio -5.09 x -8.69 x -619 x -324 x -33.5 x 76.2 x 61.6 x
Yield - - - - - - -
Capitalization / Revenue 9.76 x 9.05 x 19.7 x 25.3 x 30.1 x 11.1 x 9.33 x
EV / Revenue 11.2 x 9.14 x 15.9 x 21.2 x 30.1 x 8.8 x 7.4 x
EV / EBITDA -7.27 x -12 x 220 x -243 x -38.8 x 32 x -
EV / FCF -4.48 x -21.4 x -137 x -63.7 x - -68.5 x 1,682 x
FCF Yield -22.3% -4.67% -0.73% -1.57% - -1.46% 0.06%
Price to Book 2.51 x 5.09 x 3.21 x 3.5 x - 2.46 x 2.39 x
Nbr of stocks (in thousands) 169,284 206,375 300,232 304,290 305,946 306,161 -
Reference price 2 27.45 47.00 111.5 123.0 100.5 83.10 83.10
Announcement Date 3/29/20 3/25/21 3/30/22 3/20/23 3/22/24 - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 476.1 1,072 1,697 1,481 1,023 2,286 2,726
EBITDA 1 -734 -813.9 122.4 -129.2 -793.1 628 -
EBIT 1 -847.7 -986 -60.52 -333.4 -1,032 434 282
Operating Margin -178.05% -91.99% -3.57% -22.51% -100.91% 18.99% 10.34%
Earnings before Tax (EBT) 1 -860.9 -1,041 -42.39 -115.2 -913.6 467 413
Net income 1 -860.9 -1,042 -42.58 -115.5 -915.2 332 413
Net margin -180.83% -97.19% -2.51% -7.8% -89.49% 14.52% 15.15%
EPS 2 -5.390 -5.410 -0.1800 -0.3800 -3.000 1.090 1.350
Free Cash Flow 1 -1,192 -457.4 -196.6 -493.3 - -293.5 12
FCF margin -250.4% -42.68% -11.58% -33.31% - -12.84% 0.44%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - 2.91%
Dividend per Share - - - - - - -
Announcement Date 3/29/20 3/25/21 3/30/22 3/20/23 3/22/24 - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 656.6 423.5 361.5 336.6 361.6 421.3 216.3 138.3 211.5 456.6 219.7 380 712.5 735.5
EBITDA 1 366 54.15 12.95 -35.58 -89.36 -17.24 -162.9 -198.3 -141.4 - -141 118 156 512
EBIT 1 320.2 7.657 -35.19 -85.45 -141.8 -71.01 -220.5 -255.9 -199.4 -356.2 -214 -88 215 196.5
Operating Margin 48.76% 1.81% -9.73% -25.39% -39.2% -16.85% -101.91% -185.03% -94.29% -78.02% -97.42% -23.16% 30.18% 26.72%
Earnings before Tax (EBT) 1 332.3 2.182 14.19 6.787 -27.16 -109 -203.2 -193.6 -111.3 -405.5 -103.6 -66.5 237 214
Net income 1 332.1 3.094 13.85 6.418 -27.56 -108.2 -203.5 -194.1 -111.7 -405.9 -104 -75 224.5 167
Net margin 50.57% 0.73% 3.83% 1.91% -7.62% -25.69% -94.07% -140.3% -52.84% -88.91% -47.35% -19.74% 31.51% 22.71%
EPS 2 1.340 0.0200 0.0500 0.0200 -0.0900 -0.3600 -0.6700 -0.6400 -0.3700 -1.330 -0.3400 -0.2450 0.7400 0.5500
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/12/21 3/30/22 5/13/22 8/12/22 11/11/22 3/20/23 5/15/23 8/9/23 11/13/23 3/22/24 5/15/24 - - -
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 691 100 - - - - -
Net Cash position 1 - - 6,498 6,006 - 5,333 5,257
Leverage (Debt/EBITDA) -0.941 x -0.1233 x - - - - -
Free Cash Flow 1 -1,192 -457 -197 -493 - -294 12
ROE (net income / shareholders' equity) -43.7% -55.4% -0.69% -1.09% - 3.3% 3.9%
ROA (Net income/ Total Assets) -26.9% -28.7% -0.56% -0.99% - 2.9% 3.6%
Assets 1 3,197 3,626 7,638 11,644 - 11,448 11,472
Book Value Per Share 2 11.00 9.230 34.70 35.10 - 33.80 34.80
Cash Flow per Share 2 -4.630 -2.180 -0.1300 -0.4900 - 1.320 -
Capex 1 408 38.1 167 346 - 457 612
Capex / Sales 85.71% 3.56% 9.82% 23.35% - 19.97% 22.45%
Announcement Date 3/29/20 3/25/21 3/30/22 3/20/23 3/22/24 - -
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
83.1 TWD
Average target price
132.5 TWD
Spread / Average Target
+59.45%
Consensus
  1. Stock Market
  2. Equities
  3. 6589 Stock
  4. Financials EirGenix Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW